Fusion Pharmaceuticals Profit Margin

The latest profit margin for FUSN is -292.29% as of March 2024. That compares with -10176.33% in the prior-year period — up 97.1% year over year. That is below the Healthcare sector average of 13.39%. Investors often review this figure alongside Fusion Pharmaceuticals's historical trend and sector peers before judging valuation or financial health.

Over the past year, FUSN's profit margin moved from -10176.33% to -292.29% — a 97.1% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Fusion Pharmaceuticals's valuation or profitability profile.

Against Healthcare companies, FUSN currently prints -292.29% for profit margin, while the sector average sits near 13.39%. That is roughly 2283.5% below the sector mean. Large gaps often invite a closer look at Fusion Pharmaceuticals's growth, margins, and balance sheet.

Profit Margin shows how effectively Fusion Pharmaceuticals converts resources into returns. At -292.29%, FUSN may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with -10176.33% in the prior-year period — up 97.1% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting FUSN's profit margin (-292.29%), review year-over-year change from -10176.33%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.